EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial
Status:
Unknown status
Trial end date:
2020-10-30
Target enrollment:
Participant gender:
Summary
Based on the current evidence, empagliflozin could reduce cardiovascular morbidity and
mortality in Diabetes Mellitus Type 2 (T2DM). Anti-PCSK9 therapy (evolocumab) can reduce the
major cardiovascular events incidence in secondary prevention individuals, some of them
presenting T2DM. The beneficial effect of the combined use of these two agents in T2DM
remains unknown. Evaluating the effect of evolocumab on top of the best of care therapy for
T2DM, including empaglifozin, on endothelial function may indicate the existence of some
benefit related to cardiovascular outcomes.